{"url_path":"/sec/mmed/8-k/2026-06-29/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/2062583/0001104659-26-078588-index.html","accession_number":"0001104659-26-078588","cik":"0002062583","ticker":"MMED","issuer_name":"MiniMed Group, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2062583/0001104659-26-078588-index.html","primary_entity_key":"0002062583","primary_entity_name":"MiniMed Group, Inc."},"word_count":247,"has_tables":true,"body_markdown":"**Item 5.02**\n**Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n \n\nOn June 25,\n2026, the Board of Directors (the “Board”) of MiniMed Group, Inc. (“MiniMed”) increased the size of the\nBoard from nine to 11 and appointed David Endicott and Linnea Burman to serve as a directors of the Board to fill the resulting vacancies,\neffective June 29, 2026.\n\n \n\nMr. Endicott will serve as a class I director whose term expires at\nthe 2026 annual meeting of stockholders and will be a member of the Board’s Compensation and Talent Committee.  \n\n \n\nMr. Endicott currently serves as Chief Executive Officer of Alcon,\nInc. (NYSE: ALC; SWX: ALC), an eye care company, and has served as a member of Alcon’s board of directors since 2019. Prior to joining\nAlcon, Inc., Mr. Endicott held senior leadership roles at various healthcare organizations, including as Chief Executive Officer and Chief\nOperating Officer of Alcon Laboratories, Inc., President of Hospira Infusion Systems at Hospira, Inc., and various commercial and regional\nleadership roles at Allergan, Inc. Mr. Endicott holds an M.B.A. from the University of Southern California and a B.A. in Chemistry from\nWhitman College.\n\nThe Board has determined that Mr. Endicott is “independent”\nin accordance with the rules of The Nasdaq Stock Market LLC, the Securities and Exchange Commission (the “SEC”) and MiniMed’s\ncorporate governance guidelines. Mr. Endicott does not have a material interest in any transaction that is required to be disclosed under"}